Beam Therapeutics is a cash-burning biotech that depends on one pipeline asset (risto-cel), with 39% short interest and earnings due in 2 days, offset by 57.8% upside to the analyst target.
Thesis pillars
- Single Asset Pipeline↓Deteriorating
- Heavy Cash Burn→Stable
- Lumpy Revenue Mixed Earnings↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 24, 2026
Beam Therapeutics Inc. (BEAM) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.33: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend.
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies single DNA bases without double-stranded breaks. The lead program, risto-cel, is an autologous hematopoietic stem cell... Read more
Sell if holding. Engine safety override at $26.33: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 60. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Beam Therapeutics Inc.
About Beam Therapeutics Inc.
Beam Therapeutics' five clinical-stage programs center on proprietary base editing technology that modifies single DNA bases without double-stranded breaks. Risto-cel, an autologous HSC therapy for sickle cell disease, showed mean HbF levels above 60% in 31 BEACON trial patients through the August 2025 data cut, with BLA submission targeted for year-end 2026. BEAM-302 for alpha-1 antitrypsin deficiency has received FDA alignment on a potential accelerated approval pathway based on AAT biomarkers evaluated over 12 months, with updated Phase 1/2 data expected in Q1 2026.
Beam Therapeutics is pre-revenue, funding operations through equity and debt financing including a facility with Sixth Street Lending Partners. The company operates a 100,000 square foot cGMP manufacturing facility in Research Triangle Park, North Carolina, designed to support ex vivo cell therapy and in vivo LNP programs, supplemented by CMOs with genetic medicine experience for initial clinical trials. The base editing platform creates outbound partnering opportunities, which the company describes as an important element of its business model, allowing it to pursue precision genetic medicine applications beyond its internal focus areas. Risto-cel uses autologous ex vivo base editing via electroporation — the same technology platform used in allogeneic HSC transplantation — while BEAM-302, BEAM-301, and BEAM-304 use lipid nanoparticle in vivo delivery to the liver, a clinically validated modality.
Show full overview
The company's near-term value is substantially concentrated in the risto-cel BLA outcome: adult and adolescent enrollment in the BEACON trial was complete and manufacturing of all doses was completed as of December 2025, with the FDA having granted orphan drug designation and RMAT designation to risto-cel. One patient in the BEACON trial died four months post-infusion from respiratory failure determined to be likely related to busulfan conditioning and unrelated to risto-cel — an adverse event the company disclosed, which illustrates the binary nature of the single pivotal data set. BLA submission timing depends on data maturity from the full 50-patient cohort and FDA review cadence.
See also: Healthcare · Biotechnology
From Beam Therapeutics Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Beam Therapeutics Inc.
Latest news
- NEWS Wedbush Adjusts Price Target on Beam Therapeutics — fiscal.ai Nov 3, 2026 neutral
- NEWS Beam Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai Nov 3, 2026
- NEWS Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate — benzinga Nov 3, 2026 negative
- NEWS Ark Investment Management Increases Position in Beam Therapeutics — fiscal.ai Nov 2, 2026
- NEWS Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? — benzinga Oct 30, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T12:10:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineristo-cel10-K Item 1: 'We expect to submit a BLA for risto-cel as early as year-end 2026'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -55.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.33: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 60. Prior stop was $24.49. Score 4.5/10, moderate confidence.
Analyst target: $42.96 (+63.2% upside). Prior stop was $24.49. Stop-loss: $24.49.
Concentration risk — Pipeline: risto-cel; Quality below floor (1.8 < 4.0); Value-trap signals (3/5): Margin compression (op margin -29.2%), Material insider selling (14 sells, 1.29% of cap), Negative free cash flow.
Beam Therapeutics Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
22 analysts rate BEAM, with a consensus score of 4.2/5. 13 analysts publish price targets averaging $49.
What does Beam Therapeutics Inc. do?Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary...
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies single DNA bases without double-stranded breaks. The lead program, risto-cel, is an autologous hematopoietic stem cell therapy for sickle cell disease in a Phase 1/2 trial with BLA submission targeted for year-end 2026; secondary programs include BEAM-302 (alpha-1 antitrypsin deficiency) and BEAM-301 (GSDIa) in Phase 1/2.